Chagas disease

Chagas disease
Name	Chagas disease
Synonyms	American trypanosomiasis

Chagas disease is an infectious disease caused by the protozoan parasite Trypanosoma cruzi, first described by Carlos Chagas in 1909. It presents with an acute febrile illness that may progress to chronic cardiac, digestive, or neurological complications decades later, and it represents a major neglected tropical disease affecting population health, migration, and healthcare systems across the Americas and beyond.

Signs and symptoms

Acute infection often causes fever, malaise, and a localized inflammatory lesion such as a chagoma or Romana's sign; symptoms can mimic presentations seen in Yellow fever, Dengue fever, Zika virus disease, Leishmaniasis, and Malaria. Many individuals enter an indeterminate chronic phase without symptoms, but chronic cardiac manifestations include dilated cardiomyopathy, arrhythmias, and heart failure similar to findings in patients of John Hunter-era descriptions of cardiomyopathy and in cohorts studied by World Health Organization programs; gastrointestinal complications such as megaesophagus and megacolon can produce dysphagia and severe constipation reminiscent of clinical pictures seen in historic studies from Buenos Aires and São Paulo. Neurological involvement may resemble syndromes cataloged by investigators at Johns Hopkins Hospital and Mayo Clinic, including stroke and autonomic dysfunction.

Cause and transmission

The etiologic agent is Trypanosoma cruzi, transmitted classically by triatomine insect vectors such as Triatoma infestans and Rhodnius prolixus, species studied in entomological surveys by teams from Oswaldo Cruz Foundation and Centers for Disease Control and Prevention. Transmission routes include vectorial transmission, congenital transmission documented in cohorts from Argentina, blood transfusion screened after policy changes influenced by Pan American Health Organization, organ transplantation examined in literature from Massachusetts General Hospital, and oral transmission via contaminated food implicated in outbreaks investigated by teams from Instituto Evandro Chagas and Universidade de São Paulo. Laboratory-acquired infections and accidental exposures have been reported in settings described at Pasteur Institute and London School of Hygiene and Tropical Medicine.

Pathophysiology

Trypanosoma cruzi alternates between trypomastigote and amastigote forms, invading host cells and inducing inflammatory responses explored in research from Harvard Medical School, University of Oxford, Max Planck Institute for Infection Biology, and National Institutes of Health. Cardiac damage results from a combination of parasite persistence, immune-mediated myocarditis, and microvascular disturbances analyzed in animal models developed at Rockefeller University and Massachusetts Institute of Technology. Enteric nervous system destruction leading to megasyndromes has been characterized by histopathologic studies at University of Buenos Aires and Universidade Federal do Rio de Janeiro. Genetic diversity of T. cruzi strains with distinct discrete typing units has implications for virulence and clinical outcomes described by researchers at Instituto Nacional de Saúde Dr. Ricardo Jorge and Universidad Nacional Autónoma de México.

Diagnosis

Acute infection is diagnosed by direct demonstration of trypomastigotes in blood using microscopy or concentration techniques employed in laboratories such as Charité – Universitätsmedizin Berlin and Institut Pasteur. Serological assays including ELISA and immunofluorescence used by reference centers like Evandro Chagas Institute and Walter Reed Army Institute of Research detect anti-T. cruzi antibodies in chronic phases; confirmatory testing algorithms mirror approaches recommended by World Health Organization and European Centre for Disease Prevention and Control expert panels. Molecular diagnostics using PCR are applied in research settings at Karolinska Institutet and Institut Pasteur de Montevideo for parasite detection in congenital infection and post-treatment monitoring.

Prevention

Vector control programs employing insecticide spraying, housing improvements, and community interventions have been spearheaded by initiatives from Pan American Health Organization, Ministry of Health (Brazil), Ministry of Health (Argentina), and nongovernmental partners such as Doctors Without Borders. Blood donor screening policies implemented after guidance by World Health Organization and American Red Cross reduced transfusion transmission; maternal screening and prenatal care protocols in clinics influenced by Centers for Disease Control and Prevention and National Health Service (England) aim to detect congenital infection. Food safety regulations addressing oral transmission have been developed following outbreak investigations involving public health teams from Instituto Nacional de Salud (Peru) and Fundação Oswaldo Cruz.

Treatment

Antiparasitic therapy with benznidazole or nifurtimox is recommended for acute, congenital, and selected chronic cases, with treatment regimens refined in clinical trials conducted at Hospital de Clínicas de Porto Alegre and University of Texas Southwestern Medical Center. Management of chronic cardiac disease follows standards of care used in cardiology centers such as Cleveland Clinic and Johns Hopkins Hospital including antiarrhythmics, device therapy, and heart transplantation, with post-transplant infectious disease protocols influenced by teams at Mayo Clinic and Imperial College London. Gastrointestinal complications may require surgical interventions similar to procedures performed at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo.

Epidemiology and public health impact

Chagas disease is endemic in many parts of Latin America with historic elimination campaigns reducing domiciliary vector presence in countries such as Brazil, Argentina, Chile, and Uruguay through programs coordinated by Pan American Health Organization and national ministries. Migration has created disease prevalence in nonendemic settings with surveillance and care needs reported in United States, Spain, Italy, Japan, and Australia; public health responses have involved institutions like Centers for Disease Control and Prevention, National Institutes of Health, European Centre for Disease Prevention and Control, and World Health Organization. The disease contributes substantially to disability-adjusted life years and health system burdens studied by Global Burden of Disease Study researchers and economic analyses produced by teams at World Bank and Inter-American Development Bank.

Category:Protozoal diseases